loading
전일 마감가:
$1.27
열려 있는:
$1.3
하루 거래량:
362.74K
Relative Volume:
0.36
시가총액:
$59.37M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-0.7651
EPS:
-1.66
순현금흐름:
$-54.24M
1주 성능:
+15.45%
1개월 성능:
-23.49%
6개월 성능:
-67.52%
1년 성능:
-89.57%
1일 변동 폭
Value
$1.23
$1.31
1주일 범위
Value
$1.08
$1.39
52주 변동 폭
Value
$0.9857
$13.50

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
명칭
Cabaletta Bio Inc
Name
전화
(267) 759-3100
Name
주소
2929 ARCH STREET, PHILADELPHIA, PA
Name
직원
164
Name
트위터
@CabalettaBio
Name
다음 수익 날짜
2025-03-31
Name
최신 SEC 제출 서류
Name
CABA's Discussions on Twitter

CABA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CABA
Cabaletta Bio Inc
1.27 59.37M 0 -67.68M -54.24M -1.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-20 다운그레이드 Evercore ISI Outperform → In-line
2024-12-19 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-10-10 개시 UBS Buy
2024-02-05 개시 Jefferies Buy
2023-11-29 개시 William Blair Outperform
2023-10-24 개시 Cantor Fitzgerald Overweight
2023-10-19 개시 Stifel Buy
2023-09-05 개시 Citigroup Buy
2023-07-18 개시 Guggenheim Buy
2023-01-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-08-30 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-12-08 개시 Wells Fargo Overweight
2021-10-19 재개 Morgan Stanley Overweight
2021-06-30 개시 Mizuho Buy
2021-01-08 개시 Chardan Capital Markets Buy
2020-10-13 개시 H.C. Wainwright Buy
2019-11-19 개시 Cowen Outperform
2019-11-19 개시 Evercore ISI Outperform
2019-11-19 개시 Morgan Stanley Overweight
모두보기

Cabaletta Bio Inc 주식(CABA)의 최신 뉴스

pulisher
Apr 25, 2025

CABA’s Financial Health: Exploring Cabaletta Bio Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com

Apr 25, 2025
pulisher
Apr 24, 2025

Is Cabaletta Bio Inc (CABA) a good investment opportunity? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

American Superconductor Corp (AMSC) requires closer examination - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Aehr Test Systems (AEHR) shows promising results - uspostnews.com

Apr 24, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Cabaletta Bio Q1 EPS Estimate Increased by HC Wainwright - MarketBeat

Apr 09, 2025
pulisher
Apr 08, 2025

William Blair Boosts Earnings Estimates for Cabaletta Bio - MarketBeat

Apr 08, 2025
pulisher
Apr 08, 2025

William Blair Forecasts Cabaletta Bio Q1 Earnings - MarketBeat

Apr 08, 2025
pulisher
Apr 07, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Apr 07, 2025
pulisher
Apr 06, 2025

Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN

Apr 06, 2025
pulisher
Apr 06, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company - MarketBeat

Apr 06, 2025
pulisher
Apr 05, 2025

HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings - MarketBeat

Apr 05, 2025
pulisher
Apr 05, 2025

Cantor Fitzgerald Weighs in on Cabaletta Bio FY2025 Earnings - MarketBeat

Apr 05, 2025
pulisher
Apr 05, 2025

UBS Group Issues Pessimistic Forecast for Cabaletta Bio (NASDAQ:CABA) Stock Price - MarketBeat

Apr 05, 2025
pulisher
Apr 05, 2025

Thrivent Financial for Lutherans Buys New Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat

Apr 05, 2025
pulisher
Apr 05, 2025

Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at Guggenheim - MarketBeat

Apr 05, 2025
pulisher
Apr 05, 2025

William Blair Increases Earnings Estimates for Cabaletta Bio - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Cabaletta Bio (NASDAQ:CABA) Issues Earnings Results, Meets Estimates - MarketBeat

Apr 04, 2025
pulisher
Apr 04, 2025

Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright - MarketBeat

Apr 04, 2025
pulisher
Apr 04, 2025

William Blair Comments on Cabaletta Bio Q1 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Analysts Offer Predictions for Cabaletta Bio FY2029 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

FY2025 EPS Forecast for Cabaletta Bio Raised by Analyst - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio’s (CABA) “Buy” Rating Reaffirmed at Guggenheim - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Wells Fargo & Company Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com

Apr 01, 2025
pulisher
Apr 01, 2025

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Mar 31, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Reports Wider Q4 Results As R&D Expenses Rise - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio, Inc. SEC 10-K Report - TradingView

Mar 31, 2025

Cabaletta Bio Inc (CABA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):